Michael Higgins
Stock Analyst at Ladenburg Thalmann
(1.74)
# 3,355
Out of 5,015 analysts
21
Total ratings
29.41%
Success rate
5.55%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $20.99 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $69 | $15.27 | +350.23% | 3 | Apr 8, 2024 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $1.67 | +319.16% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $0.77 | +1,848.05% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $360 | $4.51 | +7,882.26% | 2 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $100.82 | -65.28% | 3 | Mar 2, 2023 | |
| PHGE BiomX | Maintains: Buy | $130 → $80 | $0.58 | +13,591.60% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | $105 | $8.33 | +1,160.50% | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | $29 | $33.21 | -12.68% | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $3.37 | - | 1 | Sep 27, 2017 |
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $20.99
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $15.27
Upside: +350.23%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $1.67
Upside: +319.16%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $0.77
Upside: +1,848.05%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $360
Current: $4.51
Upside: +7,882.26%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $100.82
Upside: -65.28%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.58
Upside: +13,591.60%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $8.33
Upside: +1,160.50%
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $33.21
Upside: -12.68%
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $3.37
Upside: -